Pyxis Oncology
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2019-01-01
- Employees
- 50
- Market Cap
- $216.9M
- Website
- http://www.pyxisoncology.com
- Introduction
Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Boston, MA.
Study of PYX-201 in Solid Tumors
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Pyxis Oncology, Inc
- Target Recruit Count
- 80
- Registration Number
- NCT05720117
- Locations
- 🇺🇸
SCRI - HealthOne Denver, Denver, Colorado, United States
🇺🇸University of Chicago Medicine, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Study of PYX-106 in Solid Tumors
- Conditions
- Solid Tumor
- Interventions
- Drug: PYX-106
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Pyxis Oncology, Inc
- Target Recruit Count
- 60
- Registration Number
- NCT05718557
- Locations
- 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸University of California San Diego, La Jolla, California, United States